Inovio Pharmaceuticals Inc. Common Stock (INO)

About INO

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates deliver…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

112

Website

www.inovio.com/

Fundamentals

1-day range

$1.15$1.32

Market cap

$69.62M

P/E (trailing)

—

P/E (forward)

-2.95

EPS (trailing)

$-1.70

Dividend yield

—

Beta

1.67

Avg. volume

3.07M

Forecasts

3 analyst ratings

Inovio Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• INO

  Inovio Pharmaceuticals Inc. Common Stock

  $1.28

  ▲ 1.59%
  Market cap $69.62MP/E —
  $0.5632$2.98
• XBIT

  XBiotech Inc. Common Stock

  $2.27

  ▼ 0.00%
  Market cap $69.51MP/E —
  $2.09$3.55
• CLNN

  Clene Inc. Common Stock

  $4.23

  ▼ 5.48%
  Market cap $68.24MP/E —
  $3.88$13.5
• CING

  Cingulate Inc. Common Stock

  $5.32

  ▼ 2.21%
  Market cap $68.02MP/E —
  $3.16$11.89
• CYPH

  Cypherpunk Technologies Inc. Common Stock

  $1.71

  ▼ 9.52%
  Market cap $71.74MP/E —
  $0.27$3.7
• RNTX

  Rein Therapeutics Inc. Common Stock

  $0.7621

  ▼ 2.67%
  Market cap $67.45MP/E —
  $0.694$2.18
• ELTX

  Elicio Therapeutics Inc. Common Stock

  $2.86

  ▼ 4.67%
  Market cap $72.28MP/E —
  $2.66$16

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
  Benzinga · 8/28/2026
• Inovio: The Final Countdown To A Binary FDA Decision
  SeekingAlpha · 8/25/2026
• Jefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3
  Benzinga · 8/13/2026
• Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ...
  Yahoo · 8/13/2026
• Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
  Yahoo · 8/13/2026
• Inovio Pharmaceuticals Q2 Earnings Call Highlights
  Yahoo · 8/13/2026
• Inovio Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/12/2026
• INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
  Yahoo · 8/12/2026

• Michael John Sumner · May 20, 2026 · Grant

  37.7K
• Michael John Sumner · May 20, 2026 · Grant

  46.9K
• Michael John Sumner · May 20, 2026 · Option Exercise

  9.4K
• Michael John Sumner · May 20, 2026 · Tax Withholding

  2.7K @ $1.23
• Jacqueline Elizabeth Shea · May 20, 2026 · Grant

  100.2K
• Jacqueline Elizabeth Shea · May 20, 2026 · Grant

  123.8K
• Jacqueline Elizabeth Shea · May 20, 2026 · Option Exercise

  28.3K
• Jacqueline Elizabeth Shea · May 20, 2026 · Tax Withholding

  12.3K @ $1.23
• Ann Calby Miller · May 20, 2026 · Grant

  34.2K
• Ann Calby Miller · May 20, 2026 · Grant

  41.8K
• Laurent Humeau · May 20, 2026 · Grant

  27.4K
• Laurent Humeau · May 20, 2026 · Grant

  34.2K
• Laurent Humeau · May 20, 2026 · Option Exercise

  6.0K
• Laurent Humeau · May 20, 2026 · Tax Withholding

  2.2K @ $1.23
• Roger D. Dansey · May 20, 2026 · Grant

  34.2K

Institutional Ownership

March 31, 2026

Total shares held

31.60M

Total value held

$54.48M

Institutional holders

97